Tue. Sep 29th, 2020

Fxtriangle | Market analysis | Managed trading

Fxtriangle will make Fx trading look easy.

Albuterol launch to boost Lupin US revenue, but there’s little room for error

1 min read

Lupin is finally set to launch its inhalation drug Albuterol after it received the US FDA nod for the product. Lupin had filed the application for the drug in 2017, and started manufacturing the product in July. However, the Street is looking for a quick-ramp up of sales in the US, and a follow-up with other launches. The stock has been flat in trade on Wednesday.

While the product is expected to improve US revenues substantially in the coming years, Lupin’s US revenues had hit a rough patch in the first quarter, which dented the enthusiasm for its stock lately. But with this launch, the Street is factoring in a significant upside in earnings over the next two years. Any set back in the earnings growth could hamper its stock price.

The launch is expected to add about $80-90 million in sales in the coming year, say analysts. The drug Albuterol currently accounts for about $1 billion in sales in the US. Lupin is expected to garner a decent share of the market.

This launch will help boost its US revenues, which has seen a sharp decline in the last quarter. Seasonally lower sales of generic Tamiflu and the recall of metformin dealt a heavy blow to Lupin’s US sales in the last quarter which contracted 25% quarter-on-quarter in Q1.

Leave a Reply

Forex trading and any instruments related to Foreign Exchange Market are Speculative and carry substantial risk of loss of either partial equity or the entire deposit amount. Leverage adds up to the risk, before considering to invest in this venture, you should first consider your financial position and may seek the help of an independent financial advisor. FXtriangle dis-recommends the usage of loan instruments to trade in this market as it can hamper financial position. Please do not invest the money that you cannot afford to lose. FXtriangle provides all its services throughout the Globe Excluding (Nigeria, British Virgin Island & the Islamic Republic of Iran) and also provides limited service in some jurisdictions where investment in Overseas markets / Fx Exchanges are prohibited by Law If you are not sure to contact us before using any of our services. FXtriangle acts as an Independent Corporate Financial Advisor and connects you to various overseas exchanges and cannot be held liable for any financial damage occurring through their side. All of our partnered institutions are regulated in various jurisdictions.FXtriangle conducts an independent background check before partnering with any institutions to fulfill your investment objectives smoothly. The usage of our Business name, Logo or any trademark in any financial forum, website, review website, complaint arena, Billboards without our written permission will attract lawsuits.